Castle Biosciences, Inc. Common Stock (CSTL)
SERVICES-MEDICAL LABORATORIES
- Headquarters
- United States
- Employees
- 1,002
- Market Cap
- $979M
About Castle Biosciences, Inc. Common Stock
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
SentiSense also tracks daily options readings for Castle Biosciences, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Castle Biosciences, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.